FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to immunology, and can be used for treatment tumor necrosis factor receptor-associated periodic syndrome (TRAPS). That is ensured by the therapeutic agent comprising an IL-1 beta antibody-binding antibody, wherein the antibody contains: a first domain having the amino acid sequence SEQ ID NO: 1, and second domain having amino acid sequence SEQ ID NO: 2. Group of inventions also relates to a pharmaceutical composition containing said antibody, and to a method of treating TRAPS.
EFFECT: use of this group of inventions enables to use the produced drug containing IL-1 beta antibody-binding of a person for treating tumor necrosis factor receptor-associated periodic syndrome.
19 cl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL APPLICATION OF IL-1β COMPOUNDS | 2012 |
|
RU2571563C2 |
| NEW APPLICATION OF IL-1β COMPOUNDS | 2006 |
|
RU2468817C2 |
| HUMAN ANTIBODIES TO IL-β1 | 2001 |
|
RU2286351C2 |
| RECOMBINED ANTIBODY TO HUMAN INTERLEUKIN 1β | 2001 |
|
RU2264413C2 |
| ANTIBODIES RAISED TO HUMAN MCP-1 | 2001 |
|
RU2314316C2 |
| METHOD FOR OBTAINING BI-SPECIFIC ANTIBODIES, BI-SPECIFIC ANTIBODIES AND THERAPEUTIC APPLICATION OF SUCH ANTIBODIES | 2018 |
|
RU2795240C2 |
| FORMULATIONS CONTAINING ANTIBODIES | 2009 |
|
RU2745601C2 |
| THERAPEUTIC BINDING MOLECULES | 2002 |
|
RU2328506C2 |
| APPLICATION OF CD25-BINDING MOLECULES FOR TREATMENT OF STEROID-RESISTANT PATIENTS | 2002 |
|
RU2318537C2 |
| DRUGS FOR TREATING DISEASES | 2010 |
|
RU2598719C2 |
